Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
Current studies indicate that about 4 out of 10 women have symptoms of PMS, with many women suffering from PMS experiencing a sharp increase in craving for high-sweet and high-fat foods just before menstruation. This behavior is particularly upsetting among those women who are also overweight, which totals about 20 percent of all women of childbearing age. Endorphins, which are natural opioids, are released when sweets and high fat content foods are consumed, and the endorphins can eventually cause a form of food addiction that can be exacerbated by such disorders as PMS. Dr. David Sinclair of the National Institute for Health and Welfare in Finland and the Chief Scientific Officer of Lightlake previous work in the field of addiction has shown that endorphin-reinforced addictions are gradually weakened and removed with medicines called opioid antagonists.
Lightlake Therapeutics Inc. is currently conducting a randomized double blind placebo controlled trial in Helsinki of its patented treatment for extinguishing binge eating using the opioid antagonist, naloxone. In developing a similar treatment for PMS overeating, Lightlake plans to conduct multi-center clinical trials in the near future to address this global healthcare issue.
SOURCE Lightlake Therapeutics Inc.